Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 5;12(1):27.
doi: 10.1186/s12245-019-0240-0.

Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature

Alexis Diaz-Ramos  1 , Wesley Eilbert  2 , Diego Marquez  3
Affiliations

Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature

Alexis Diaz-Ramos et al. Int J Emerg Med. .

Abstract

Background: The sodium-glucose cotransporter-2 (SGLT2) inhibitors are the newest class of anti-hyperglycemic medications used in the treatment of diabetes mellitus. Their increasing use has been driven by their apparent cardiovascular and renal benefits. They have been associated with a small but significantly increased risk of diabetic ketoacidosis (DKA). Many of the cases of DKA associated with SGLT2 inhibitor use present with normal or minimally elevated serum glucose levels, often delaying the diagnosis.

Case presentation: A 44-year-old woman with diabetes mellitus presented to our emergency department complaining of 3 days of generalized weakness. The SGLT2 inhibitor canagliflozin had been added to her medication regimen 4 weeks earlier, and she had stopped using insulin 2 weeks prior to presentation. Laboratory evaluation revealed a metabolic acidosis with an elevated anion gap and the presence of serum acetone, despite a minimally elevated serum glucose of 163 mg/dL. The patient was treated for euglycemic DKA with intravenous infusions of insulin and dextrose, with resolution of her symptoms in 3 days.

Conclusions: The SGLT2 inhibitors are a novel class of anti-hyperglycemic medications that are being used with increasing frequency in the treatment of diabetes mellitus. They are associated with a small but significantly increased risk of DKA. Many of the patients presenting with DKA associated with SGLT2 inhibitor use will have normal or minimally elevated serum glucose levels. This unusual presentation of DKA can be diagnostically challenging.

Keywords: Euglycemic DKA; Euglycemic diabetic ketoacidosis; SGLT2 inhibitor DKA; SGLT2 inhibitor euglycemic DKA; Sodium-glucose cotransporter-2 inhibitor diabetic ketoacidosis; Sodium-glucose cotransporter-2 inhibitor euglycemic diabetic ketoacidosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The possible mechanism of euglycemic diabetic ketoacidosis caused by SGLT2 inhibitor use
See this image and copyright information in PMC

References

    1. Kitabachi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crisis in adults with diabetes. Diabetes Care. 2009;32:1335–1343. doi: 10.2337/dc09-9032. - DOI - PMC - PubMed
    1. Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycemic diabetic ketoacidosis. Br Med J. 1973;2:578–580. doi: 10.1136/bmj.2.5866.578. - DOI - PMC - PubMed
    1. Modi A, Agrawal A, Morgan F. Euglycemic ketoacidosis: a review. Curr Diabetes Rev. 2017;13(13):315–321. doi: 10.2174/1573399812666160421121307. - DOI - PubMed
    1. Rawla P, Vellipuram AR, Bandaru SS, Predeep Raj J. Euglycemic diabetes ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017. 10.1530/EDM-17-0081. - PMC - PubMed
    1. FDA news release. FDA approves Invokana to treat type 2 diabetes. https://wayback.archive-it.org/7993/20170112023858/https://www.fda.gov/N.... Accessed 8 Mar 2019.

LinkOut - more resources